News Snapshot:
China approves first COVID-19 vaccine patent to CanSino Biologics Last month, the medical journal Lancet wrote that the Phase-2 clinical trial of CanSino Biologics' adenovirus vector vaccine or Ad5-nCoV was safe and induced immune response BusinessToday.In 12 IST China's vaccine maker CanSino Biologics Inc has won the patent approval for its COVID-19 vaccine candidate Ad5-nCoV China's vaccine maker CanSino Biologics Inc, on Monday, won the patent approval for its COVID-19 vaccine candidate Ad5-nCoV, according to the Chinese Intellectual Property Administration. It is the first COVID-19 vaccine patent granted by China, according to state-owned newspaper People's Daily. The patent was submitted...
